Abstract:Chronic hepatitis C virus infection represents a serious global public health problem, typically resulting in fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. Based on our previous discovery of lead compound 2 (Liu et al. J Med Chem 54:5747–5768, 2011 ), 35 new quinoxalinone derivatives were explored in this study. Outline of the structure–activity relationships (SARs) revealed that compound BH6870 ( 36 ) showed high anti-HCV potency ( EC_50 = 0.21 M ) and a good cell safety index (SI = 47.19 ). SARs analysis indicated that quinoxalin-2(1 H )-one containing a 4-aryl-substituted thiazol-2-amine moiety was optimal for antiviral activity. Introducing a hydrogen-bond acceptor (such as ester or amide group) at the C-3 position of quinoxalin-2(1 H )-one was beneficial for the antiviral potency, and especially, N , N -disubstituted amide was far superior to N -monosubstituted amide. Incorporation of more than one halogen (fluorine or chlorine atom) or a strong electron-withdrawing group on the benzene ring of the thiazole-phenyl moiety might reduce electron atmosphere density further and resulted in a dramatical loss of activity. The NH-group of the lactam moiety was clearly required for anti-HCV activity. Graphical Abstract Design and synthesis of quinoxalin-2(1 H )-one derivatives as new non-nucleoside small-molecule HCV inhibitors. BH6870 ( 36 ), showing higher antiviral potency and a good cell safety index, was identified.

Synthesis and biological evaluation of HQCAs with aryl or benzyl substituents on N-1 position as potential HIV-1 integrase inhibitors

Synthesis and Biological Evaluation of 5-Fluoroquinolone-3-carboxylic Acids As Potential HIV-1 Integrase Inhibitors.

Synthesis and Neuroprotective Biological Evaluation of Quinazolinone Derivatives Via Scaffold Hopping.

Structural Modifications of Quinolone-3-carboxylic Acids with Anti-Hiv Activity

Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.

Design,synthesis and activity evaluation of new anti-HIV-1 CXCR4 inhibitors

Quinazolinone-based subchemotypes for targeting HIV-1 capsid protein: design and synthesis

QSAR of 1-cyclopropyl-6-fluoro-7-substituted-1,4-dihydro 4-oxoquinoline-3-carboxylic acids for anti-HIV activity

QSAR of 1-cyclopropyl-6-fluoro-7-substituted-1,4-dihydro-4-oxoquinoline-3-carboxylic acids for anti-HTV activity

Synthesis, Characterization, and Biological Evaluation of Some Novel Quinoxaline Derivatives as Antiviral Agents

Synthesis and Biological Activity of Benzo[h]quinolinium Hydrazine Compounds

Structure–activity relationship studies on quinoxalin-2(1 H )-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870

Design and Synthesis of P/m‐[p‐(un)substituted Phenylsulfonamido]phenyl Β‐diketo Acids and Quinoxalone Derivatives.

Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators

Synthesis and Biological Evaluation of Dihydroquinazoline-2-amines As Potent Non-Nucleoside Reverse Transcriptase Inhibitors of Wild-Type and Mutant HIV-1 Strains.

Design, Synthesis and Cu2+ Recognition Ofβ-Diketoacid and Quinoxalone Derivatives Bearing Caffeoyl or Galloyl Moieties Linked by Arylamide As Potential HIV Integrase Inhibitors

Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.

Quantitative Structure-Activity Relationships of Hiv-1 Integrase Inhibitors of Dkas

Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors

Quinolines and isoquinolines as HIV-1 inhibitors: Chemical structures, action targets, and biological activities

Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.